Companywide revenue for the quarter increased 247% compared with the second quarter of 2023 and increased 5% compared to the first quarter of 2024. The company had a net loss for the quarter of $780,000, which included approximately $540,000 in non-cash stock option compensation expense. At June 30, 2024, the company had $4.8 million in cash and cash equivalents, and $10.1 million total assets. The company’s total stockholder’s equity increased to $5.9 million as of June 30, 2024. BioLargo’s President and CEO Dennis P. Calvert said of the results, “We had another quarter of record revenues, and we continue to strengthen our balance sheet. We are in a strong position to continue advancing the commercialization of our multiple cleantech products and services.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLGO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue